Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Real-time Estimate Cboe Europe  -  03:23:00 2023-02-09 am EST
1511.50 GBX   +0.70%
02/08Why Europe's drug shortages may get worse
RE
02/07GSK to Expand Use of Clinical Trial Design Platform Solara in New Three-year Deal
MT
02/07Oil Stocks Help Lead European Equities Modestly Higher Tuesday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Valneva shares fall as French health body advises against its COVID-19 vaccine

12/08/2022 | 05:13am EST
FILE PHOTO: Illustration shows Valneva logo

PARIS (Reuters) - Shares in France's Valneva reversed course on the Paris stock market and traded down by around 2.8% after the country's public health authority said it would advise the government not to use the company's COVID-19 vaccine for its vaccination strategy.

(Reporting by Tassilo Hummel; Editing by Sudip Kar-Gupta)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 1.04% 1515.8 Delayed Quote.4.41%
NOVAVAX, INC. -4.13% 10.44 Delayed Quote.1.56%
SANOFI 1.05% 89.62 Real-time Quote.-1.48%
VALNEVA SE -1.53% 6.21 Real-time Quote.-0.71%
All news about GSK PLC
02/08Why Europe's drug shortages may get worse
RE
02/07GSK to Expand Use of Clinical Trial Design Platform Solara in New Three-year Deal
MT
02/07Oil Stocks Help Lead European Equities Modestly Higher Tuesday
MT
02/07GSK's India unit posts 9% rise in Q3 profit as input costs slump
RE
02/06GSK Vows To Boost Diversity In Clinical Trial Enrollments Following 17-year Retrospecti..
MT
02/06FTSE 100 Closed Down 0.8% Amid Strong US Jobs Data
DJ
02/06Gsk : announces results from 17-year retrospective study on US clinical trial diversity
PU
02/03Gsk: morgan stanley cuts target price to 1485p from 1520p…
RE
02/02GSK plc - Benlysta granted Orphan Drug Designation by US FDA for the potential treatmen..
AQ
02/02GSK : Credit Suisse gives a Neutral rating
MD
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 29 105 M 35 125 M 35 125 M
Net income 2022 6 339 M 7 651 M 7 651 M
Net Debt 2022 14 349 M 17 317 M 17 317 M
P/E ratio 2022 9,04x
Yield 2022 4,06%
Capitalization 60 567 M 73 095 M 73 095 M
EV / Sales 2022 2,57x
EV / Sales 2023 2,58x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 1 501,00 GBX
Average target price 1 695,23 GBX
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC4.41%73 095
JOHNSON & JOHNSON-7.38%427 756
ELI LILLY AND COMPANY-7.15%323 754
NOVO NORDISK A/S3.50%315 573
MERCK & CO., INC.-3.88%270 375
ABBVIE INC.-10.52%255 653